Detalhe da pesquisa
1.
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.
Lancet
; 397(10277): 892-901, 2021 03 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33676628
2.
BETA PRIME: Phase I study of AdAPT-001 as monotherapy and combined with a checkpoint inhibitor in superficially accessible, treatment-refractory solid tumors.
Future Oncol
; 18(29): 3245-3254, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35950603
3.
Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial.
Lancet Oncol
; 21(12): 1661-1672, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33271095
4.
BETA prime: a first-in-man phase 1 study of AdAPT-001, an armed oncolytic adenovirus for solid tumors.
Cancer Gene Ther
; 31(4): 517-526, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38146006
5.
Operational Metrics for the ELAINE 2 Study Combining a Traditional Approach With a Just-in-TIME Model.
JCO Clin Cancer Inform
; 7: e2200164, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37352479
6.
First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1).
J Clin Oncol
; 40(23): 2530-2538, 2022 08 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35167329
7.
Maximum Tolerated Dose and Anti-Tumor Activity of Intraperitoneal Cantrixil (TRX-E-002-1) in Patients with Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer: Phase I Study Results.
Cancers (Basel)
; 13(13)2021 Jun 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-34206826
8.
Five-year results of a phase II trial of preoperative 5-fluorouracil, epirubicin, cyclophosphamide followed by docetaxel with capecitabine (wTX) (with trastuzumab in HER2-positive patients) for patients with stage II or III breast cancer.
Cancer Med
; 7(6): 2288-2298, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29582557